Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF2R | P11717 | 4/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.44 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.44 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | PYGB | P11216 | 1/20 | 0.41 |
| ▸ | MMP1 | P03956 | 1/20 | 0.41 |
| ▸ | MMP7 | P09237 | 1/20 | 0.41 |
| ▸ | MMP8 | P22894 | 1/20 | 0.41 |
| ▸ | MMP12 | P39900 | 1/20 | 0.41 |
| ▸ | MMP13 | P45452 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12500147 | 1.00 | IGF2R (0.49) | IGF2RGAALGALS8LGALS3LGALS4 | |
| SCHEMBL15316746 | 0.90 | IGF2R (0.63) | IGF2RLGALS8LGALS3LGALS4 | |
| SCHEMBL15316754 | 0.89 | LGALS8 (0.52) | IGF2RGAALGALS8LGALS3LGALS4 | |
| SCHEMBL12500148 | 0.89 | LGALS8 (0.52) | IGF2RGAALGALS8LGALS3LGALS4 | |
| SCHEMBL11432204 | 0.89 | LGALS8 (0.52) | IGF2RGAALGALS8LGALS3LGALS4 | |
| SCHEMBL11432196 | 0.89 | LGALS8 (0.52) | IGF2RGAALGALS8LGALS3LGALS4 | |
| SCHEMBL10602258 | 0.87 | IGF2R (0.43) | IGF2RGAALGALS8LGALS3LGALS4 | |
| SCHEMBL10602265 | 0.87 | IGF2R (0.43) | IGF2RGAALGALS8LGALS3LGALS4 | |
| SCHEMBL31047717 | 0.83 | IGF2R (0.52) | IGF2RGAALGALS8LGALS3LGALS4 | |
| SCHEMBL12500145 | 0.81 | IGF2R (0.39) | IGF2RGAACA2MAPK1PYGB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130274210-A1 | DENDRIMERS WITH A SACCHARIDE ENDING FOR ANTI-INFLAMMATORY PURPOSES | UNIVERSITE PAUL SABATIER TOULOUSE III (FR) | 2013-10-17 | — | — | US | disclosed |
| US-20130274210-A1 | DENDRIMERS WITH A SACCHARIDE ENDING FOR ANTI-INFLAMMATORY PURPOSES | UNIVERSITE PAUL SABATIER TOULOUSE III (FR) | 2013-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130274210-A1 | DENDRIMERS WITH A SACCHARIDE ENDING FOR ANTI-INFLAMMATORY PURPOSES | CD44, SELE, CD68 | IGF2R 1228/4885GAA 464/4885LGALS8 57/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.